Compare HQY & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQY | BLCO |
|---|---|---|
| Founded | 2002 | 1853 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Ophthalmic Goods |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 5.9B |
| IPO Year | 2014 | 2022 |
| Metric | HQY | BLCO |
|---|---|---|
| Price | $83.94 | $16.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $115.00 | $18.45 |
| AVG Volume (30 Days) | ★ 940.9K | 362.5K |
| Earning Date | 06-03-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.69 | N/A |
| EPS | ★ 2.46 | N/A |
| Revenue | $229,525,000.00 | ★ $5,101,000,000.00 |
| Revenue This Year | $8.57 | $8.65 |
| Revenue Next Year | $8.42 | $5.59 |
| P/E Ratio | $33.52 | ★ N/A |
| Revenue Growth | ★ 28.68 | 6.47 |
| 52 Week Low | $72.76 | $10.45 |
| 52 Week High | $116.65 | $18.92 |
| Indicator | HQY | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 47.19 |
| Support Level | $81.37 | $14.27 |
| Resistance Level | $84.21 | $17.11 |
| Average True Range (ATR) | 3.53 | 0.39 |
| MACD | -0.17 | -0.03 |
| Stochastic Oscillator | 64.22 | 37.67 |
HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.